Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Banco Vida Corp.
WARNING LETTER
•Banco Vida Corp.•September 18, 2019

Banco Vida Corp. – FDA Warning Letter, Sep 18, 2019

Record Details

The FDA conducted inspections of Banco Vida Corporation and Laboratorio Banco Vida from September 9-18, 2019, documenting significant deviations from Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) regulations (21 CFR 1271). Key violations include the failure to adequately screen donors for all relevant communicable disease risk factors, such as hepatitis B/C, West Nile Virus, and Zika virus, and the use of an unapproved syphilis test kit for donor screening. The firm also failed to adequately control environmental conditions, specifically lacking monitoring of the biological safety cabinet used for umbilical cord blood processing, and did not validate its HPC-C Manufacturing process. Further deficiencies involved processing HCT/Ps in a manner that risked cross-contamination, a lack of investigation into positive post-processing cultures, and inadequate procedures for donor eligibility, particularly regarding Zika virus risk. The FDA acknowledged the firm's responses but noted ongoing concerns, emphasizing that current ZIKV tests are not appropriate for HCT/Ps and that donors from ZIKV risk areas must be deemed ineligible and products labeled accordingly. The letter requires prompt corrective actions, a written response within 15 working days detailing steps taken to correct violations and prevent recurrence, and warns of potential regulatory action if non-compliance persists.

Company
Banco Vida Corp.
Inspection date
September 18, 2019
Product type
Biologics
Office
Office of Biological Product Operations
Person
  • Elizabeth A. Waltrip (Program Division Director)
View Company Profile

ID · 30f4c14d-0486-4d6d-a6c8-36966a0be22f

Violation Codes9
21 CFR 1271.75(a)21 CFR 1271.80(c)21 CFR 1271.195(a)21 CFR 1271.230(a)21 CFR 1271.220(a)21 CFR 1271.160(b)(6)21 CFR 1271.47(a)21 CFR 1271.65(b)(1)21 CFR 1271.65(b)(2)

Full citation text and observation details available on the Dashboard.

Other documents for Banco Vida Corp.
  • 483 - 2021-08-12August 12, 2021
  • EIR - 2021-08-12August 12, 2021
  • 483 - 2019-09-18September 18, 2019
  • EIR - 2019-09-18September 18, 2019
  • WARNING_LETTER - 2019-09-18September 18, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Banco Vida Corp.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.